The early administration of the WT1 peptide vaccine after tumor collapse is expected to cause rapid clonal expansion of WT1-specific CTLs, which can attack WT1-expressing tumors and lead to a favorable clinical response. This evidence concerns the gene WT1 and neoplasm.